Li Y. et al. (2022) reported that Notch pathway was correlated with TIME in SCLC. Notch1 gene mutation was negatively linked to PD-L1 expression in SCLC patients. Higher expression of DLL3 was found in SCLC patients and associated with PD-L1 levels. Hence, SCLC patients with positive DLL3 expression and Notch1 wild type had PD-L1 overexpression, which could be likely to have good immunotherapy efficacy. Notch2 mutation was a prognostic factor in NSCLC patients and could be provide a new treatment option for patients without EGFR mutations (Niu et al., 2021). The gene discussed is DLL3; the disease is non-small cell lung carcinoma.